Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.
You may also be interested in...
After more than a decade, the field of transcatheter mitral valve therapy is still in its infancy, yet it is surprisingly crowded. The first percutaneous mitral valve company was founded in 1999, the same year that the first transcatheter aortic valve implantation (TAVI) company was founded, but while TAVI is now on the market in Europe and in the US, the leading transcatheter mitral valve therapy has only just completed clinical trials.
Brief summaries of recent medtech market and industry developments. This month we cover new scrutiny of metal-on-metal hip implants, new developments in reimbursement for carotid artery stenting, and a new report on shifting hospital purchasing patterns.
Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.